SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Biglari Holdings Reports Q3 Results; Steak n Shake Sales Rise 18.2%

Biglari Holdings reported third-quarter and first nine months of 2026 results. Steak n Shake domestic company- and franchise-operated restaurant same-store sales increased 18.2% in Q3; no prior-period comparison was provided.

BH
SquawkNews Desk 1 updates Updated Nov 06, 2026, 09:37 PM UTC

Story updates

09:37:06 PM UTC
SquawkNews
OverviewOutlookResult DriversCompany press release:Key DetailsReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automati…

Biglari Holdings announced third-quarter and first nine months of 2026 results. Steak n Shake domestic company- and franchise-operated restaurant same-store sales increased 18.2% in Q3; no prior-period comparison was provided for this sales figure.Material DetailsContext by AI AnalystThis is a quar…

Related stories

IonQ Reports Q3 Revenue Beat, Raises 2026 Guidance IonQ said demand for its Superion 256 quantum computers is strong and that it has sold out its 2027 capacity. Morgan Stanley maintained an equal-weight rating and cut its price tar M impact | EQUITY | Nov 06, 2026, 10:34 PM UTC TEN Holdings Q3 Revenue Rises 17.9% to $640,000; Net Loss Widens Third-quarter 2026 revenue rose 17.9% year over year to $640,000. Net loss widened to $3.734 million from $1.987 million a year earlier; gross profit was $379,000, with a 59.2% mar M impact | EQUITY | Nov 06, 2026, 10:33 PM UTC bioAffinity Technologies Reports Q3 2026 Revenue of About $1.1 Million The company reported a net loss of $5.3 million. Year-to-date testing revenue rose 79% to about $1.1 million, and CyPath Lung test sales doubled versus the first nine months of 202 M impact | EQUITY | Nov 06, 2026, 10:33 PM UTC Ventum Raises 5N Plus Price Target to $45 From $44 Ventum Capital Markets analyst Daniel Lavoie maintained a Buy rating, raised his price target to $45.00 from $44.00 and increased revenue and earnings forecasts through 2028. M impact | EQUITY | Nov 06, 2026, 10:32 PM UTC Quoin Pharmaceuticals Reports $4.9 Million Q3 Loss and Positive QRX003 Interim Data Quoin reported a $4.9 million net loss for the third quarter of 2026, versus $3.9 million a year earlier, and $33.2 million in cash, cash equivalents and investments at September-e M impact | EQUITY | Nov 06, 2026, 10:23 PM UTC Week Ahead Sentiment: Quiet Week Post Stock Market Bloodbath L impact | EQUITY | Nov 06, 2026, 10:21 PM UTC